%0 Journal Article
%T Tratamiento adyuvante en c¨¢ncer de colon: Nuestra experiencia
%A Meza
%A Carolina
%A P¨¦rez
%A Mar¨ªa Angelina
%A Fuentes
%A Mar¨ªa Bel¨¦n
%A Cabello
%A Alberto
%A Rodr¨ªguez
%A Juan Jos¨¦
%A Col¨®n
%A Virgilio
%A Oblitas
%A George
%A Romero
%A Mar¨ªa Carolina
%A Thomas
%A Elerdina
%A Villegas
%A Carlos
%A Garc¨ªa
%A Cristina
%A Chen
%A Luz M
%A Lion
%A Lorena
%A Palacios
%A Luis E
%A Mari£¿o
%A Juan Carlos
%A Paz
%A Carlos
%J Revista Venezolana de Oncolog¨ªa
%D 2011
%I Scientific Electronic Library Online
%X colon cancer is one of the most common tumors in our country. following surgery, adjuvant chemotherapy has shown benefit for patients at high risk and node-positive, so it is considered standard modality. objective: the aim of this study is to evaluate the experience of our institution as far as this treatment modality, referred for five years. results: preliminarily we evaluated total of 118 patients, the gender distribution was equal. left colon tumors, occupied the highest percentage (45.76 %) and the most common histology was adenocarcinoma. with regard to tnm, t3 was the most frequent (53.1 %) and n0 also (46.9 %). of the sample assessed, 63.2 % received adjuvant chemotherapy, being the most widely used schemes, folfox 4 62.5 %, xelox 18.1 % and capecitabine 13.9 %. 66.7 % of patients had adverse events, being the most frequent diarrhea, nausea, vomiting, and peripheral neuropathy, all g1/2 in most cases. there were no treatment-related deaths. 100 % of patients had follow-up, for the year 2009, 55.93 % of them were alive. the os was greater in the group that received adjuvant treatment with regard to that it did not receive it, without statistics significant (p=0.098) since up to the date there has not been reached the median of global survival. conclusions: similar results were obtained with regard to the dfs, being this major in the group that received chemotherapy, versus the group that did not receive it, reached significant statistics (p=0.045).
%K colon
%K cancer
%K chemotherapy
%K adjuvant
%K overall survival
%K disease
%K free survival.
%U http://www.scielo.org.ve/scielo.php?script=sci_abstract&pid=S0798-05822011000200003&lng=en&nrm=iso&tlng=en